Clinical utility of novel agents in the treatment of central venous catheter occlusion

Supportive Cancer Therapy

Volumn 3, Issue 3, 2006, Pages 135-139

  Reddy, G Kesava ^a  

^a CIG Media Group   (United States)

Author keywords

Alfimeprase; Alteplase; Reteplase; Thrombolytic agents

Indexed keywords

ALFIMEPRASE; ALPHA 2 MACROGLOBULIN; ALTEPLASE; CYTOTOXIC AGENT; FIBRINOLYTIC AGENT; ORPHAN DRUG; PLACEBO; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANAPHYLAXIS; BLEEDING; BLOOD CLOT; BLOOD SAMPLING; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RISK; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPOTENSION; INCIDENCE; LABORATORY TEST; NUTRITIONAL SUPPORT; RASH; SHORT SURVEY; SINGLE DRUG DOSE; THROMBOSIS; UNITED STATES;

EID: 33745770619     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.010     Document Type: Review

References (15)

1. Alfimeprase: a novel, first-in-class thrombolytic (blood clot dissolver). Available at: http://www.nuvelo.com/news/documents/Alfimeprasebrochure3.06.pdf. Accessed April 2006.
2. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines trial. J Clin Oncol 2002; 20:317-324.
3. Cobos E, Dixon S, Keung YK. Prevention and management of central venous catheter thrombosis. Curr Opin Hematol 1998; 5:355-359.
4. Lokich JJ, Bothe A Jr, Benotti P, et al. Complications and management of implanted venous access catheters. J Clin Oncol 1985; 3:710-717.
5. Medical Association Communications. Keeping the lines open: managing central venous catheter occlusions and related complications in adult and pediatric oncology patients. 2001 Annual Congress of the Oncology Nursing Society Symposia Highlights. Available at: http://www.macmcm.com/ons/ons2001_ 05.htm. Accessed January 8, 2002.
6. National Institutes of Health Drug Information Service. Management of central venous catheter occlusions. Pharmacy Update. November/December 1999. Available at: http://www.cc.nih.gov/phar/updates/99nov-dec.html. Accessed January 8, 2003.
7. Hartnell GG, Gates J. The case of Abbokinase and the PDA: the events leading to the suspension of abbokinase supplies in the United States. J Vasc Interv Radiol 2000; 11:841-847.
8. Liu CY, Jain V, Shields AF, et al. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. J Vasc Interv Radial 2004; 15(1 pt 1):39-44.
9. Deitcher SR. Prevention and Treatment of Catheter Occlusion. Presented at: 4th Annual future of supportive therapy in oncology; February 24-26, 2006; Dallas, TX.
10. Ouriel K, Cynamon J, Weaver FA, et al. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 2005; 16:1075-1083.
11. Deitcher S, Moll S, Kenyon P, et al. Safety and efficacy of alfimeprase for restoring function in occluded central venous catheters: interim results of a phase 2, multicenter, randomized, double-blind study (NuCath). Presented at: American Society of Hematology 46th Annual Meeting and Exposition; December 2004; San Diego, CA. Abstract #1768.
12. Ouriel K. Safety and efficacy of alfimeprase for catheter-directed thrombolysis in patients with acute peripheral arterial occlusion: report of a phase 2, multi-center, multi-national, open-label, dose-escalation study (NAPA-1). Presented at: Cardiovascular Research Foundation's (CRF) Sixteenth Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium; September 2004; Washington, DC.
13. Guan AL, Retzios AD, Henderson GN, et al. Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (Agkistrodon contortrix contortrix). Arch Biochem Biophys 1991; 289:197-207.
14. Haire WD, Atkinson JB, Stephens LC, et al. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 1994; 72:543-547.
15. Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12:951-955.